2001
DOI: 10.1002/1097-0215(200102)9999:9999<::aid-ijc1181>3.0.co;2-q
|View full text |Cite
|
Sign up to set email alerts
|

HPV16 L1E7 chimeric virus-like particles induce specific HLA-restricted T cells in humans afterin vitro vaccination

Help me understand this report

Search citation statements

Order By: Relevance

Paper Sections

Select...
3
1
1

Citation Types

0
36
0
1

Year Published

2003
2003
2021
2021

Publication Types

Select...
8
2

Relationship

0
10

Authors

Journals

citations
Cited by 62 publications
(37 citation statements)
references
References 26 publications
0
36
0
1
Order By: Relevance
“…Due to efforts by many investigators [2,4,6,7,11,14,18,22,32], numerous CD8 T-cell epitopes of HPV 16 E6 and E7 proteins have been described, and CD8 epitopes relevant to the vast majority of the population are known. On the other hand, only a handful of HPV-specific CD4 T-cell epitopes have been described [i.e., E7 50-62 (33 amino acids long) restricted by DR15, E7 43-77 (35 amino acids long) restricted by DR3, and E7 35-50 (16 amino acids long) restricted by DQ2 described by van der Burg et al [30]; and E7 61-80 (20 amino acids long) restricted by DR9 described by Okubo et al [19].…”
Section: Discussionmentioning
confidence: 99%
“…Due to efforts by many investigators [2,4,6,7,11,14,18,22,32], numerous CD8 T-cell epitopes of HPV 16 E6 and E7 proteins have been described, and CD8 epitopes relevant to the vast majority of the population are known. On the other hand, only a handful of HPV-specific CD4 T-cell epitopes have been described [i.e., E7 50-62 (33 amino acids long) restricted by DR15, E7 43-77 (35 amino acids long) restricted by DR3, and E7 35-50 (16 amino acids long) restricted by DQ2 described by van der Burg et al [30]; and E7 61-80 (20 amino acids long) restricted by DR9 described by Okubo et al [19].…”
Section: Discussionmentioning
confidence: 99%
“…At least in some cases Ag presentation by DCs is the limiting factor in antitumor immunity (31). Vaccines comprising DCs pulsed with TAA-derived peptides, recombinant tumor proteins, virus-like particles containing TAA, and apoptotic tumor cells have proved effective in generating tumor protection in animal models (3,(32)(33)(34), and in generation of tumor Ag-specific T cell responses in vitro in humans (35)(36). DC immunogens genetically modified to express TAA can improve on the pulsing approach by providing more prolonged Ag stimulation (37,38).…”
Section: Discussionmentioning
confidence: 99%
“…Strategies that use DCs to deliver TAAs have shown considerable promise in inducing tumor Ag-directed CD8 Ï© CTL responses and curtailment of tumor growth (1). Thus, DCs pulsed with TAA-derived peptides, recombinant tumor proteins, virus-like particles containing TAA, and apoptotic tumor cells have proved effective in generating tumor protection in animal models (30 -32) and in generation of tumor Ag-specific T cell responses in vitro in humans (33,34). DC immunogens genetically modified to express TAA improve on the approach of pulsing DCs with peptide before infusion, by providing more prolonged antigenic stimulation (35,36).…”
Section: Discussionmentioning
confidence: 99%